Lymphoma Research Foundation gives $3.5M in grants to 28 researchers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Lymphoma Research Foundation has awarded 28 new research grants in 2024, amounting to $3.5 million to cancer researchers who will advance understanding of lymphoma and lay the foundation for improved patient care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of conditional marketing authorization of Tepkinly (epcoritamab), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. 
Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
In the phase III STARGLO study of Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy, the Columvi regiment extended overall survival.